KR101633728B1 - 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도 - Google Patents

변이체 액티빈 수용체 폴리펩타이드 및 이의 용도 Download PDF

Info

Publication number
KR101633728B1
KR101633728B1 KR1020147010346A KR20147010346A KR101633728B1 KR 101633728 B1 KR101633728 B1 KR 101633728B1 KR 1020147010346 A KR1020147010346 A KR 1020147010346A KR 20147010346 A KR20147010346 A KR 20147010346A KR 101633728 B1 KR101633728 B1 KR 101633728B1
Authority
KR
South Korea
Prior art keywords
glu
gly
leu
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147010346A
Other languages
English (en)
Korean (ko)
Other versions
KR20140056393A (ko
Inventor
정훈 선
레이-팅 토니 탐
쿠 한
케이쓰 수-녕 크와크
지아오란 조우
Original Assignee
암젠 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인코퍼레이티드 filed Critical 암젠 인코퍼레이티드
Publication of KR20140056393A publication Critical patent/KR20140056393A/ko
Application granted granted Critical
Publication of KR101633728B1 publication Critical patent/KR101633728B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
KR1020147010346A 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도 Expired - Fee Related KR101633728B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90545907P 2007-03-06 2007-03-06
US60/905,459 2007-03-06
US6547408P 2008-02-11 2008-02-11
US61/065,474 2008-02-11
PCT/US2008/003119 WO2008109167A2 (en) 2007-03-06 2008-03-06 Variant activin receptor polypeptides and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008467A Division KR101428344B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157003616A Division KR101633727B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20140056393A KR20140056393A (ko) 2014-05-09
KR101633728B1 true KR101633728B1 (ko) 2016-06-28

Family

ID=39739001

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020147010346A Expired - Fee Related KR101633728B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020127008467A Expired - Fee Related KR101428344B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020167016449A Abandoned KR20160075861A (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020097020320A Ceased KR20090127146A (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020157003616A Expired - Fee Related KR101633727B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020127008467A Expired - Fee Related KR101428344B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020167016449A Abandoned KR20160075861A (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020097020320A Ceased KR20090127146A (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
KR1020157003616A Expired - Fee Related KR101633727B1 (ko) 2007-03-06 2008-03-06 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도

Country Status (29)

Country Link
US (5) US7947646B2 (enExample)
EP (2) EP3141605A1 (enExample)
JP (1) JP5496682B2 (enExample)
KR (5) KR101633728B1 (enExample)
CN (2) CN101679980B8 (enExample)
AR (1) AR065611A1 (enExample)
AU (1) AU2008223338C9 (enExample)
BR (1) BRPI0808332A2 (enExample)
CA (1) CA2679841C (enExample)
CL (2) CL2008000664A1 (enExample)
CR (2) CR11054A (enExample)
CY (1) CY1118857T1 (enExample)
DK (1) DK2132314T3 (enExample)
EA (2) EA201490822A1 (enExample)
ES (1) ES2613043T3 (enExample)
HR (1) HRP20170323T1 (enExample)
HU (1) HUE032260T2 (enExample)
IL (2) IL200605A (enExample)
LT (1) LT2132314T (enExample)
MX (3) MX389715B (enExample)
NZ (1) NZ579369A (enExample)
PE (3) PE20130615A1 (enExample)
PH (1) PH12013502308A1 (enExample)
PL (1) PL2132314T3 (enExample)
PT (1) PT2132314T (enExample)
RS (1) RS55726B1 (enExample)
SI (1) SI2132314T1 (enExample)
TW (3) TWI454479B (enExample)
WO (1) WO2008109167A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP3269381B1 (en) 2005-11-23 2020-10-07 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8063188B2 (en) 2006-09-05 2011-11-22 Eli Lilly And Company Anti-myostatin antibodies
DK2468290T3 (en) 2006-12-18 2015-06-01 Acceleron Pharma Inc Activin-ActRII antagonists for use in the treatment of anemia
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN103920139B (zh) 2007-02-01 2018-02-02 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CA2677605C (en) 2007-02-09 2016-01-19 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT3494986T (pt) 2008-08-14 2020-07-14 Acceleron Pharma Inc Armadilhas para gdf
AU2016210719B2 (en) * 2008-11-26 2018-03-29 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
MY159483A (en) * 2008-11-26 2017-01-13 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
AU2013216639B2 (en) * 2008-11-26 2016-05-05 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EA201650137A1 (ru) 2009-04-27 2017-09-29 Новартис Аг Композиции и способы для усиления мышечного роста
MX2011013172A (es) 2009-06-08 2012-04-02 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) * 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP3818988A1 (en) 2009-11-03 2021-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
PE20131340A1 (es) 2010-08-16 2013-11-29 Amgen Inc Polipeptidos que enlazan miostatina, composiciones y metodos
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
MX344840B (es) 2010-11-12 2017-01-09 Colgate Palmolive Co Producto de cuidado oral y metodos de uso y fabricación de los mismos.
SI2726099T1 (sl) * 2011-07-01 2018-11-30 Novartis Ag Postopek za zdravljenje metaboličnih motenj
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PL2780368T3 (pl) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
AU2012364736A1 (en) * 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9434779B2 (en) 2012-03-19 2016-09-06 The Brigham And Women's Hospital, Inc. Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure
PE20150642A1 (es) 2012-06-11 2015-05-26 Amgen Inc Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos
CA2889286A1 (en) 2012-10-24 2014-05-01 Celgene Corporation Methods for treating anemia
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
HK1218553A1 (zh) 2013-02-01 2017-02-24 Santa Maria Biotherapeutics, Inc. 抗激活素a化合物对受试者的施用
EP2968463A4 (en) * 2013-03-15 2016-11-23 Amgen Inc MYOSTATINANTAGONISM IN HUMAN PATIENTS
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015073396A1 (en) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
AU2015274293A1 (en) * 2014-06-13 2017-02-02 Amgen Inc. Formulated receptor polypeptides and related methods
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
IL252631B2 (en) 2014-12-03 2024-06-01 Celgene Corp ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
WO2016092439A1 (en) * 2014-12-08 2016-06-16 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
US9744985B2 (en) 2015-02-17 2017-08-29 Hyundai Motor Company Rack bar unit of vehicle steering device
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
PL3280727T3 (pl) 2015-04-06 2021-07-19 Acceleron Pharma Inc. Jednoramienne białka fuzyjne receptora typu I i typu II i ich zastosowania
AU2016244750B2 (en) 2015-04-06 2021-02-18 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
MX2017013520A (es) * 2015-04-22 2018-05-22 Alivegen Usa Inc Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
IL301476A (en) 2016-01-06 2023-05-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CA3043180A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
CN112292144B (zh) 2018-01-12 2025-03-21 科乐斯疗法公司 激活素受体iib型变体及其使用方法
JP7579706B2 (ja) 2018-03-01 2024-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 体組成を変更するための方法
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4444747A1 (en) * 2021-12-10 2024-10-16 Biogen MA Inc. Modified actriib proteins and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899886A (en) * 1959-08-18 rodth
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5349966A (en) 1976-10-18 1978-05-06 Hitachi Ltd Manufacture of semiconductor integrated circuit
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US20050186593A1 (en) * 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
DE69114277T2 (de) * 1991-07-05 1996-06-27 Nestle Sa Gerät zum Extrahieren von Kartuschen, brauchbar für jede Espressomaschine.
ATE146749T1 (de) * 1991-07-05 1997-01-15 Nestle Sa Stabile kaffeekassette und verfahren zu ihrer herstellung
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5827733A (en) 1993-03-19 1998-10-27 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 (GDF-8) and polynucleotides encoding same
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PT1129190E (pt) 1998-11-13 2007-08-08 Immunex Corp Adn e polipéptidos de tslp humanos.
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
JP2000262405A (ja) * 1999-03-18 2000-09-26 Soc Prod Nestle Sa 飲料抽出用密封カートリッジ
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
TWI236360B (en) * 2000-06-30 2005-07-21 Nestle Sa Capsule cage
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DK1190959T3 (da) * 2000-09-26 2004-06-28 Nestle Sa Lukket indsats, der er beregnet til fremstilling af en drik ved udtrækning under tryk
EP1203554A1 (fr) * 2000-11-03 2002-05-08 Societe Des Produits Nestle S.A. Dispositif pour l'extraction d'une substance alimentaire contenue dans un élément de recharge
DK1208782T3 (da) * 2000-11-28 2004-12-13 Nestle Sa Perkolationsindretning
US20050188854A1 (en) * 2002-02-07 2005-09-01 The Coca-Cola Co. Coffee and tea dispenser
US6786134B2 (en) * 2002-02-07 2004-09-07 The Coca-Cola Company Coffee and tea dispenser
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
FR2842092B1 (fr) * 2002-07-12 2004-12-24 Seb Sa Machine a cafe fonctionnant avec des doses
SI1581649T1 (sl) 2002-12-20 2011-09-30 Amgen Inc Vezna sredstva, ki zavirajo miostatin
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
US8327754B2 (en) * 2003-07-22 2012-12-11 The Coca-Cola Company Coffee and tea pod
US20060196364A1 (en) * 2003-07-22 2006-09-07 The Coca-Cola Company Coffee & Tea Pod
DK3395339T3 (da) 2003-09-12 2019-07-22 Amgen Inc Hurtigt opløsende formulering af cinacalcet-hcl
US7074445B2 (en) * 2003-10-30 2006-07-11 Frito-Lay North America, Inc. Method for adhering large seasoning bits to a food substrate
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
GB2411106B (en) * 2004-02-17 2006-11-22 Kraft Foods R & D Inc Cartridge for the preparation of beverages
CN1997356A (zh) 2004-04-23 2007-07-11 安姆根有限公司 持续释放制剂
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
GB2416480B (en) * 2004-07-27 2007-12-27 Kraft Foods R & D Inc A system for the preparation of beverages
US20060034831A1 (en) * 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
MX2007003320A (es) 2004-09-24 2007-05-18 Amgen Inc Moleculas fc modificadas.
EP1640756A1 (en) * 2004-09-27 2006-03-29 Barco N.V. Methods and systems for illuminating
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
NZ566774A (en) 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
ATE402882T1 (de) * 2005-10-14 2008-08-15 Nestec Sa Kapsel zur bereitung eines getränks
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20080014860A1 (en) * 2006-07-14 2008-01-17 Lynn Byron Heitman Method and apparatus for eliminating register boxes, improving penetration sealing, improving airflow and reducing the labor costs to install ceiling registers
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
DK2468290T3 (en) 2006-12-18 2015-06-01 Acceleron Pharma Inc Activin-ActRII antagonists for use in the treatment of anemia
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
US8431175B2 (en) * 2007-06-05 2013-04-30 Nestec S.A. Method for preparing a beverage or food liquid and system using brewing centrifugal force
JP5082676B2 (ja) * 2007-08-23 2012-11-28 株式会社サタケ 光学式穀物選別機
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US20100015144A1 (en) 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
PT2299851T (pt) * 2008-07-08 2018-11-29 Nestle Sa Sistema de nutrição controlado por porção e método utilizando cápsulas
US8151694B2 (en) * 2008-08-01 2012-04-10 Keurig, Incorporated Beverage forming apparatus with centrifugal pump
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT3494986T (pt) 2008-08-14 2020-07-14 Acceleron Pharma Inc Armadilhas para gdf
JP5457455B2 (ja) * 2008-09-02 2014-04-02 ネステク ソシエテ アノニム 遠心力を使用した制御型飲料製造装置
MY159483A (en) 2008-11-26 2017-01-13 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EA201650137A1 (ru) 2009-04-27 2017-09-29 Новартис Аг Композиции и способы для усиления мышечного роста
MX2011013172A (es) 2009-06-08 2012-04-02 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
US20120295814A1 (en) 2010-01-08 2012-11-22 The Brigham And Women's Hospital, Inc. CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
AU2012364736A1 (en) 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013106715A1 (en) 2012-01-13 2013-07-18 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor

Also Published As

Publication number Publication date
HUE032260T2 (en) 2017-09-28
ES2613043T3 (es) 2017-05-22
SI2132314T1 (sl) 2017-03-31
IL248322A0 (en) 2016-11-30
US20180072791A1 (en) 2018-03-15
KR101428344B1 (ko) 2014-08-13
US7947646B2 (en) 2011-05-24
MX389715B (es) 2025-03-20
US8716459B2 (en) 2014-05-06
CA2679841A1 (en) 2008-09-12
AR065611A1 (es) 2009-06-17
KR20120065374A (ko) 2012-06-20
CN101679980B8 (zh) 2017-02-22
US20140194355A1 (en) 2014-07-10
MX2009009495A (es) 2009-09-15
PE20171325A1 (es) 2017-09-11
CA2679841C (en) 2022-03-08
AU2008223338A1 (en) 2008-09-12
TW200846359A (en) 2008-12-01
PH12013502308A1 (en) 2015-12-02
TWI573802B (zh) 2017-03-11
TW201718635A (zh) 2017-06-01
CL2008000664A1 (es) 2008-06-13
KR101633727B1 (ko) 2016-06-28
EA201490822A1 (ru) 2014-11-28
CN101679980A (zh) 2010-03-24
US9447165B2 (en) 2016-09-20
AU2008223338C9 (en) 2013-07-04
US9809638B2 (en) 2017-11-07
US20110183897A1 (en) 2011-07-28
KR20090127146A (ko) 2009-12-09
RS55726B1 (sr) 2017-07-31
KR20160075861A (ko) 2016-06-29
CR20150094A (es) 2015-04-14
AU2008223338B2 (en) 2012-12-20
NZ579369A (en) 2012-02-24
CR11054A (es) 2009-10-30
CN101679980B (zh) 2016-05-11
CL2015003139A1 (es) 2016-07-15
EP2132314B1 (en) 2016-11-30
IL200605A0 (en) 2011-08-01
PL2132314T3 (pl) 2017-07-31
PT2132314T (pt) 2017-03-02
BRPI0808332A2 (pt) 2014-07-08
PE20130615A1 (es) 2013-07-01
US20090227497A1 (en) 2009-09-10
PE20081804A1 (es) 2009-02-21
CY1118857T1 (el) 2018-01-10
EP2132314A2 (en) 2009-12-16
DK2132314T3 (en) 2017-02-27
JP2010519931A (ja) 2010-06-10
IL200605A (en) 2016-10-31
EP3141605A1 (en) 2017-03-15
WO2008109167A2 (en) 2008-09-12
US20160264644A1 (en) 2016-09-15
KR20150024444A (ko) 2015-03-06
EA200970810A1 (ru) 2010-06-30
EA020510B1 (ru) 2014-11-28
KR20140056393A (ko) 2014-05-09
WO2008109167A3 (en) 2009-06-18
MX348286B (es) 2017-06-02
CN105924516A (zh) 2016-09-07
LT2132314T (lt) 2017-03-27
AU2008223338C1 (en) 2013-06-20
US10407487B2 (en) 2019-09-10
TW201441254A (zh) 2014-11-01
JP5496682B2 (ja) 2014-05-21
HRP20170323T1 (hr) 2017-04-21
TWI454479B (zh) 2014-10-01

Similar Documents

Publication Publication Date Title
KR101633728B1 (ko) 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
US8501678B2 (en) Variant activin receptor polypeptides and uses thereof
US9610327B2 (en) Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
HK1235435A1 (en) Variant activin receptor polypeptides and uses thereof
HK1139983B (en) Variant activin receptor polypeptides and uses thereof
HK1139983A (en) Variant activin receptor polypeptides and uses thereof
NZ626580B2 (en) Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

Not in force date: 20190622

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190622

St.27 status event code: N-4-6-H10-H13-oth-PC1903